Events in our system are self-managed.  Group and event managers are encouraged to review privacy and security settings, and adjust them if needed.  If you need assistance please contact Indico Support - contact Help at bottom of page. https://learn.getindico.io/categories/managing/

Apr 1 – 5, 2019
Fairmont Château Laurier Hotel
UTC timezone

Radium-223 (Ra-223) therapy after abiraterone: analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Not scheduled
15m
Fairmont Château Laurier Hotel

Fairmont Château Laurier Hotel

Speaker

Dr Joe M. O'Sullivan (Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast, Northern Ireland)

Description

Background The Ra-223 Phase III study (ALSYMPCA) was conducted before abiraterone became available. The Ra-223 iEAP study included abiraterone-treated patients. Here we assessed SSEs, overall survival (OS) and bone health agent (BHA) use in Ra-223–treated patients who received abiraterone as a prior treatment. Methods This open-label, single-arm trial enrolled patients with bone-predominant mCRPC (≥2 bone metastases). Patients who received prior anti-cancer therapies were included; use of BHAs (bisphosphonates and denosumab) was permitted before/during the study. Median follow-up was 7.5 months. Baseline characteristics, SSEs, (external beam radiation therapy, symptomatic pathological fractures, spinal cord compression or surgical intervention) and OS were analyzed descriptively for patients who completed prior abiraterone therapy and abiraterone-naïve patients. Results Of 708 mCRPC patients, 85% of prior-abiraterone and 36% of abiraterone-naïve patients had previously received docetaxel. During Ra-223 therapy, 14% and 17% of patients received concomitant bisphosphonates and 20% and 17% concomitant denosumab in the prior-abiraterone and abiraterone-naïve groups, respectively. Median time since diagnosis of bone metastasis and start of Ra-223 was 37 and 21 months in the prior-abiraterone and abiraterone-naïve groups, respectively. Median PSA at baseline in the prior-abiraterone group was 290 µg/l and 100 µg/l in the abiraterone-naïve group. Median OS was 15.9 months overall (11.2 months for prior-abiraterone and 17.1 months for abiraterone-naïve patients). More patients had SSEs in the prior-abiraterone group (26%) than the abiraterone-naïve group (14%); incidence of pathological bone fractures was similar in both groups (5% for both). Conclusions Patients in the prior-abiraterone group had a longer time from diagnosis of bone metastasis to Ra-223 initiation. These patients seem to have more-advanced disease, as reflected by higher median baseline PSA and more patients with prior docetaxel therapy. Similar rates of pathological and non-pathological fractures were reported in Ra-223–treated patients regardless of prior use of abiraterone. Acknowledgments This study was funded by Bayer.
Funding Agency Bayer Pharmaceuticals
Email Address joe.osullivan@qub.ac.uk
Presentation Type Poster

Primary author

Dr Joe M. O'Sullivan (Centre for Cancer Research & Cell Biology, Queen's University Belfast, Belfast, Northern Ireland)

Co-authors

Dr Axel Heidenreich (Urology, University Hospital Cologne, Cologne, Germany) Dr Daniel Heinrich (Oncology, Akershus University Hospital, Oslo, Norway) Dr Fred Saad (Urology, University of Montreal Hospital Center, Montreal, QC, Canada) Jan Kalinovsky (Medical Oncology, Bayer Consumer Care AG, Basel, Switzerland) Dr Joan Carles (Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain) Dr Kurt Miller (Urology, Charité Berlin, Berlin, Germany) Dr Manfred Wirth (Urology, University Hospital Carl Gustav Carus, Dresden, Germany) Dr Sten Nilsson (Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden)

Presentation materials

There are no materials yet.